Core Viewpoint - Yisheng Biotechnology (01061) has seen a significant stock increase, rising nearly 9% in the afternoon session, with a current price of HKD 4.36 and a trading volume of HKD 5.2576 million [1] Group 1: Product Development and Exhibition - The company will participate in the 2026 Asia-Pacific Academy of Ophthalmology (APAO 2026) conference from February 5 to 8 at the Hong Kong Convention and Exhibition Centre [1] - Yisheng Biotechnology will showcase two core products: EB12-20145P (Bevacizumab) and a single-dose Beifu Shuh eye drop, both of which are demonstrating strong clinical development momentum [1] - The EB12-20145P project has been selected for poster presentation at the conference, where clinical progress and research insights will be shared with the international ophthalmology community [1] Group 2: Strategic Partnerships - The company announced an exclusive distribution agreement between its wholly-owned subsidiary Majeton and Osteopore, a global leader in 3D-printed bioresorbable implants [1] - This collaboration marks a milestone for the company in the oral market and expands its product line in dental, orthodontic, and maxillofacial solutions [1] - The partnership is expected to support the company's pursuit of sustainable growth in the Chinese market [1]

Core Viewpoint - The announcement highlights a strategic partnership between Majeton Pte Ltd, a wholly-owned subsidiary of 亿胜生物科技 (Yisheng Biotechnology), and Osteopore International Pte Ltd, focusing on exclusive distribution of innovative dental, orthodontic, and maxillofacial products in China, Hong Kong, and Macau [1]. Group 1: Partnership Details - Majeton has been appointed as the exclusive distributor for Osteopore's products in the specified regions [1]. - The expected contract value of the distribution agreement exceeds RMB 12,000,000, which includes advance payments and milestone payments [1]. - Additional revenue can be generated through product procurement and supply [1]. Group 2: Market Impact - The collaboration marks a significant milestone for the company in the oral market [1]. - It expands the company's product line in dental, orthodontic, and maxillofacial solutions [1]. - The partnership is aimed at supporting the company's pursuit of sustainable growth in the Chinese market [1].